Dr. Ekamol Tantisattamo, MD

Dr. Tantisattamo practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Tantisattamo's NPI, 1104053024, was assigned on June 18, 2009. Dr. Tantisattamo graduated from Mahidol University Faculty of Medicine in 2006. Dr. Tantisattamo holds California license A151885.

Dr. Tantisattamo's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Tantisattamo's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Tantisattamo to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tantisattamo practices. Vendor and product names are available with a free account.

Nephrology is Dr. Tantisattamo's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Tantisattamo is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Tantisattamo's licenses on file in 5 states: California, Georgia, Hawaii, Michigan and Illinois.

Dmand AI lists acute kidney failure and chronic kidney disease among the conditions Dr. Tantisattamo treats.

CMS data shows 1,215 Medicare services from Dr. Tantisattamo across 7 procedure codes in 2024, for 236 Medicare patients. Medicare paid $86,995 for them.

CMS counts 236 Medicare patients who saw Dr. Tantisattamo in 2024. The largest group is under 65, with 115 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 67% are also on Medicaid. Their average risk score is 5.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tantisattamo's median patient age at 58, with 42% women.

In 2024, Dr. Tantisattamo wrote 922 Medicare Part D claims for 151 patients. 92% of them were for generic drugs. CMS names the drug for 734 of them, across 22 drugs with 11 or more claims each, at $33,267 in total drug cost. In 2023, CMS named 638 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tantisattamo for performance year 2024, reported through an alternative payment model (APM). Dr. Tantisattamo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tantisattamo as offering telehealth.

Dmand AI links 73 papers to Dr. Tantisattamo, published from 2014 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Kidney Transplantation, Kidney and Renal Insufficiency, Chronic. Dr. Tantisattamo has published most often in Curr Opin Nephrol Hypertens. Dr. Tantisattamo's most frequent co-authors are Kamyar Zadeh Kalantar-Zadeh, MD, Sharon P. Andreoli, MD and Richard J. Knight, MD.

Dmand AI links Dr. Tantisattamo to 2 clinical trials. Conditions studied include Hypertension and Vascular Diseases.

CMS Open Payments shows 22 general payments to Dr. Tantisattamo from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 65% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,816.

Dr. Tantisattamo graduated from Mahidol University Faculty of Medicine in 2006.

Dr. Tantisattamo is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.